These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 10531190

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A week-long course of inhaled beta-agonist or anticholinergic agent may reduce dyspnea during exercise in COPD.
    Teramoto S, Fukuchi Y, Ouchi Y.
    Chest; 1996 Jun; 109(6):1666-7. PubMed ID: 8769538
    [No Abstract] [Full Text] [Related]

  • 5. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD.
    Ikeda A, Nishimura K, Izumi T.
    Chest; 1996 Jan; 109(1):294. PubMed ID: 8549208
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease.
    Matera MG, Caputi M, Cazzola M.
    Respir Med; 1996 Sep; 90(8):497-9. PubMed ID: 8869445
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease.
    Cramer JA, Bradley-Kennedy C, Scalera A.
    Can Respir J; 2007 Sep; 14(1):25-9. PubMed ID: 17315055
    [Abstract] [Full Text] [Related]

  • 14. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
    Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K.
    Am J Respir Crit Care Med; 2001 Apr; 163(5):1087-92. PubMed ID: 11316640
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease.
    Chapman KR, Arvidsson P, Chuchalin AG, Dhillon DP, Faurschou P, Goldstein RS, Kuipers AF, International study group.
    Can Respir J; 2002 Apr; 9(3):178-85. PubMed ID: 12068339
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Additive effects of salmeterol and fluticasone or theophylline in COPD.
    Cazzola M, Di Lorenzo G, Di Perna F, Calderaro F, Testi R, Centanni S.
    Chest; 2000 Dec; 118(6):1576-81. PubMed ID: 11115442
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.